Broad-spectrum bacterial and fungal pathogens

Broad-spectrum bacterial and fungal pathogens represent a collective group of infectious agents rather than a specific molecular target. This category encompasses a wide array of Gram-positive and Gram-negative bacteria, as well as various yeast and mold species that cause human disease (NIH, 2023). Therapeutic strategies against these pathogens typically involve agents that interfere with highly conserved pathways, such as the synthesis of peptidoglycan in bacteria or ergosterol in fungi (StatPearls, 2023). For example, polyene antifungals target fungal membrane integrity, while carbapenem antibiotics inhibit bacterial cell wall assembly (PubMed, 2022). While these broad-spectrum treatments are vital for treating undiagnosed or polymicrobial infections, they pose significant challenges, including the promotion of antimicrobial resistance (CDC, 2022). They also frequently lead to the destruction of beneficial host flora, which can result in secondary infections like Clostridioides difficile (StatPearls, 2023). Consequently, this term is used in clinical and pharmaceutical contexts to define the breadth of activity for anti-infective drugs rather than a single biochemical receptor or enzyme. In drug development, broad-spectrum refers to the pharmacological profile of a compound capable of inhibiting a diverse range of taxonomic groups.

Other names

Broad-spectrum pathogensBacterial and fungal infectious agentsMulti-pathogen activity

Inhibition of essential microbial processes including cell wall synthesis, nucleic acid replication, and protein synthesis across diverse taxa.